These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37530186)

  • 1. [Prognostic significance of PD-L1 expression as a potential predictor of survival in gastric cancer].
    Sotnikova TN; Danilova NV; Polushkina TV; Malkov PG; Chayka AV; Khomyakov VM; Kalinin DV
    Arkh Patol; 2023; 85(4):18-23. PubMed ID: 37530186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [PD-L1 expression in EBV-associated gastric carcinomas].
    Danilova NV; Sotnikova TN; Kalinin DV; Oleynikova NA; Chayka AV; Khomyakov VM; Kakotkin VV; Vychuzhanin DV; Andreeva YY; Malkov PG
    Arkh Patol; 2022; 84(4):5-12. PubMed ID: 35880594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.
    Paliogiannis P; Lobrano R; Bella MA; Fara A; Uras MG; Pinna MA; Tedde A; Madonia M; Zinellu A; Cossu A
    Ann Diagn Pathol; 2024 Apr; 69():152267. PubMed ID: 38266544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
    J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection.
    Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Lee HS; Jeon S; Yoo TK; Park WC; Yoon CI
    Sci Rep; 2021 Oct; 11(1):19555. PubMed ID: 34599199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay.
    Gupta G; Pasricha S; Kamboj M; Sharma A; Nayana NS; Durga G; Sharma A; Rawal S; Meh A
    Indian J Pathol Microbiol; 2022; 65(4):839-843. PubMed ID: 36308190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
    Montero MA; Aricak O; Kis L; Yoshikawa A; De Petris L; Grundberg O; Pham HHN; Roden AC; Fukuoka J; Attanoos R; Guijarro R; Alarcón F; Lindström K; Ortiz-Villalón C
    Ann Diagn Pathol; 2021 Apr; 51():151701. PubMed ID: 33485052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
    Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
    Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies.
    Lawson NL; Dix CI; Scorer PW; Stubbs CJ; Wong E; Hutchinson L; McCall EJ; Schimpl M; DeVries E; Walker J; Williams GH; Hunt J; Barker C
    Mod Pathol; 2020 Apr; 33(4):518-530. PubMed ID: 31558782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
    Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
    BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types.
    Nobin H; Garvin S; Hagman H; Nodin B; Jirström K; Brunnström H
    BMC Cancer; 2024 Aug; 24(1):1051. PubMed ID: 39187798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
    Reisenbichler ES; Han G; Bellizzi A; Bossuyt V; Brock J; Cole K; Fadare O; Hameed O; Hanley K; Harrison BT; Kuba MG; Ly A; Miller D; Podoll M; Roden AC; Singh K; Sanders MA; Wei S; Wen H; Pelekanou V; Yaghoobi V; Ahmed F; Pusztai L; Rimm DL
    Mod Pathol; 2020 Sep; 33(9):1746-1752. PubMed ID: 32300181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of Three Clones of PD-L1 in Lung Cancer: A Single-center Experience.
    Park SG; Lee HJ; Lee SB; Hong R
    In Vivo; 2023; 37(1):233-241. PubMed ID: 36593005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
    Vlajnic T; Baur F; Soysal SD; Weber WP; Piscuoglio S; Muenst S
    Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):726-730. PubMed ID: 36165931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1
    Ilie M; Falk AT; Butori C; Chamorey E; Bonnetaud C; Long E; Lassalle S; Zahaf K; Vénissac N; Mouroux J; Cohen C; Brambilla E; Marquette CH; Hofman V; Hofman P
    Mod Pathol; 2016 Dec; 29(12):1552-1564. PubMed ID: 27562497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.
    Loghin A; Nechifor-Boilă A; Borda A; Nechifor-Boilă IA; Voidazan S; Decaussin-Petrucci M
    Virchows Arch; 2022 Feb; 480(2):303-313. PubMed ID: 34669047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.